tbuckley/cabot-search huggingface dataset:
Re: Prajna et al.: Cross-Linking—Assisted Infection Reduction: a randomized clinical trial evaluating the effect of adjuvant cross-linking on outcomes in fungal keratitis (Ophthalmology. 2020;127:159–166)
Authors: Farhad Hafezi, Emilio A. Torres-Netto, Mark J.P. Hillen
Journal: Ophthalmology (2020)
Creating Built Environments That Expand Active Transportation and Active Living Across the United States: A Policy Statement From the American Heart Association
Authors: Deborah R. Young, Angie L. Cradock, Amy A. Eyler, Mark Fenton, Margo Pedroso, James F. Sallis, Laurie P. Whitsel
Journal: Circulation (2020)

Physical activity is vital for the health and well-being of youth and adults, although the prevalence of physical activity continues to be low. Promoting active transportation or human-powered transportation through policy, systems, and environmental change is one of the leading evidence-based strategies to increase physical activity regardless of age, income, racial/ethnic background, ability, or disability. Initiatives often require coordination across federal, state, and local agencies. To maximize the effectiveness of all types of interventions, it is imperative to establish strong and broad partnerships across professional disciplines, community members, and advocacy groups. Health organizations can play important roles in facilitating these partnerships. This policy statement provides recommendations and resources that can improve transportation systems, enhance land use design, and provide education to support policies and environments to promote active travel. The American Heart Association supports safe, equitable active transportation policies in communities across the country that incorporate consistent implementation evaluation. Ultimately, to promote large increases in active transportation, policies need to be created, enforced, and funded across multiple sectors in a coordinated and equitable fashion. Active transportation policies should operate at 3 levels: the macroscale of land use, the mesoscale of pedestrian and bicycle networks and infrastructure such as Complete Streets policies and Safe Routes to School initiatives, and the microscale of design interventions and placemaking such as building orientation and access, street furnishings, and safety and traffic calming measures. Health professionals and organizations are encouraged to become involved in advocating for active transportation policies at all levels of government.
Reply to “COVID-19 prediction models should adhere to methodological and reporting standards”
Authors: Guangyao Wu, Henry C. Woodruff, Avishek Chatterjee, Philippe Lambin
Journal: European Respiratory Journal (2020)

<b>It is hard to follow a standardised methodology for prediction models, while researchers should adhere to generally accepted reporting standards according to research needs and journal submission requirements</b>https://bit.ly/30zfMIw
Behavioral and Social Research to Accelerate the Geroscience Translation Agenda
Authors: Terrie E. Moffitt
Journal: Ageing Research Reviews (2020)

Geroscience is the study of how to slow biological aging to extend healthspan and longevity. Geroscience has not heretofore incorporated behavioral or social-science methods or findings into its agenda, but the current expansion of the agenda to human trials of anti-aging therapies will be greatly aided by behavioral and social science. This article recommends some ways in which geroscience can be augmented through collaboration with behavioral and social science to: accomplish translation from animal models to humans; inform the design of clinical trials of anti-aging therapies; develop outcome measures for evaluating efficacy of anti-aging therapies, and reduce and not exacerbate health disparities.
Liver prometastatic reaction: Stimulating factors and responsive cancer phenotypes
Authors: Fernando Vidal-Vanaclocha, Olatz Crende, Cira García de Durango, Alejandro Herreros-Pomares, Sandra López-Doménech, Álvaro González, Eva Ruiz-Casares, Thierry Vilboux, Riccardo Caruso, Hipólito Durán, Antonio Gil, Benedetto Ielpo, Fernando Lapuente, Yolanda Quijano, Emilio Vicente, Leticia Vidal-Lartitegui, Eduardo M. Sotomayor
Journal: Seminars in Cancer Biology (2020)
Abstract 310A: Transcription factors FOXP3 regulate ATF3 expression
Authors: Wei-Hsiung Yang, Chiung-Min Wang, William Yang
Journal: Cancer Research (2020)

Abstract Activating transcription factor 3 (ATF3), a stress sensor, is rapidly induced by a variety of physiological and pathological signals, including those from cancer cells, and is essential in the complex processes of stress response. Several lines of evidence have demonstrated that ATF3 is involved in host defense and cancer development. Several studies also provide the relationship between ATF3 and p53 indicating that ATF3 binds to and stabilizes p53 while ATF3 is a negative regulator of TP53 gene expression. FOXP3, a well-known breast and prostate tumor suppressor, is a novel transcriptional repressor for several oncogenes including SKP2. However, whether ATF3 is the target protein of FOXP3 remains unknown. Herein, we demonstrate that ATF3 expression is regulated by FOXP3. First, we observed that overexpression of FOXP3 reduced ATF3 protein level in several cancer cell lines (H1299, HepG2, and Ishikawa cells). Secondly, FOXP3 dose-dependently reduced ATF3 promoter activity in gene reporter assay in several cell lines (MCF7, H1299, MDAMB231, and Saos2 cells). Since FOXP3 is regulated by post-translational modifications (PTMs), we next investigated whether PTMs affect FOXP3-mediated ATF3 expression. Interestingly, we observed that phosphorylation mutation on FOXP3 (Y342F) abolished FOXP3-mediated ATF3 expression. However, other PTM mutations on FOXP3, including S418 phosphorylation, K263 acetylation and ubiquitination, and K268 acetylation and ubiquitination, did not alter FOXP3-mediated ATF3 expression. Finally, FOXP3 binding site was found on ATF3 promoter region, around -870 bp region. Taken together, our results suggest that FOXP3 functions as a novel regulator of ATF3 and this novel event may be involved in tumor development and progression. Citation Format: Wei-Hsiung Yang, Chiung-Min Wang, William Yang. Transcription factors FOXP3 regulate ATF3 expression [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 310A.
Manganese enhances the antitumor function of CD8+ T cells by inducing type I interferon production
Authors: Yuan Song, Yonghao Liu, Huey Yee Teo, Zuhairah Binte Hanafi, Yu Mei, Ying Zhu, Yen Leong Chua, Mengze Lv, Zhengfan Jiang, Haiyan Liu
Journal: Cellular and Molecular Immunology (2020)
Ethical Considerations for COVID-19 Vaccine Trials in Correctional Facilities
Authors: Emily A. Wang, Jonathan Zenilman, Lauren Brinkley-Rubinstein
Journal: JAMA (2020)

This Viewpoint discusses the importance of studying coronavirus disease 2019 (COVID-19) vaccine candidates in prisoners, and proposes a framework for considering how to include them safely, ethically, and without coercion in future phase 3 vaccine trials.
Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy case–control study with multicohort validation
Authors: Andrée-Anne Grosset, Frédérick Dallaire, Tien Nguyen, Mirela Birlea, Jahg Wong, François Daoust, Noémi Roy, André Kougioumoutzakis, Feryel Azzi, Kelly Aubertin, Samuel Kadoury, Mathieu Latour, Roula Albadine, Susan Prendeville, Paul Boutros, Michael Fraser, Rob G. Bristow, Theodorus van der Kwast, Michèle Orain, Hervé Brisson, Nazim Benzerdjeb, Hélène Hovington, Alain Bergeron, Yves Fradet, Bernard Têtu, Fred Saad, Frédéric Leblond, Dominique Trudel
Journal: PLoS Medicine (2020)

Prostate cancer (PC) is the most frequently diagnosed cancer in North American men. Pathologists are in critical need of accurate biomarkers to characterize PC, particularly to confirm the presence of intraductal carcinoma of the prostate (IDC-P), an aggressive histopathological variant for which therapeutic options are now available. Our aim was to identify IDC-P with Raman micro-spectroscopy (RμS) and machine learning technology following a protocol suitable for routine clinical histopathology laboratories.
AB0052 Progressive symmetric arthritis as an early manifestation of adeno carcinoma of the lung
Authors: M Welcker, H Hobert, K Welcker, D Kaufmann, H Franck
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> In may 1999 a 57 year old woman presented progressive symmetric arthritis of the hand, fingers and forefoot over a period of more than 6 weeks. Laboratory testing revealed an elevated sedimentation rate, increased C reactive protein levels and secondary signs of inflammation (elevated ferritine, alpha-2-fraction in the serum electrophoreses, etc.). The radiograph showed juxtaarticular osteoporosis without further signs of joint destruction. The x-ray of the chest was normal (performed for reasons of nicotin consumption over years and the intention of methotrexate therapy) without signs of malignancy. Initially the patient was treated as an outpatient. Although the initiated DMARD-therapy with methotrexate was well tolerated at a dose of 15 mg orally per week she was finally admitted to the hospital in December 1999 for reasons of further deteriorating of the arthritis and the general feeling. Symmetrical arthritis and elevated sedimentation rate revealed continuous inflammation. An x-ray control of the hand and feet showed a fine periostal hyperostosis suspective for "osteoarthropathy hypertrophiante pneumonique Pierre Marie Bamberger". The x-ray of the chest was suspective for a malignant process of the lung, a diagnose that was confirmed by computer tomography. Histological examination revealed an adeno carcinoma of the lung. Consecutive palliative chemotherapy led to improvement of arthritis. <h3>Objectives</h3> ./. <h3>Methods</h3> ./. <h3>Results</h3> ./. <h3>Conclusion</h3> This is a case of malignant lung disease with the rare initial symptom of symmetric progressive arthritis and periostal hyperostosis, improving after chemotherapy.
Temporal trends in decompensated heart failure and outcomes during <scp>COVID</scp>‐19: a multisite report from heart failure referral centres in <scp>London</scp>
Authors: Antonio Cannatà, Daniel I. Bromage, Irfan A. Rind, Caterina Gregorio, Clare Bannister, Mohammed Albarjas, Susan Piper, Ajay M. Shah, Theresa A. McDonagh
Journal: European Journal of Heart Failure (2020)

Admission rates for acute decompensated heart failure (HF) declined during the COVID-19 pandemic. However, the impact of this reduction on hospital mortality is unknown. We describe temporal trends in the presentation of patients with acute HF and their in-hospital outcomes at two referral centres in London during the COVID-19 pandemic.A total of 1372 patients hospitalized for HF in two referral centres in South London between 7 January and 14 June 2020 were included in the study and their outcomes compared with those of equivalent patients of the same time period in 2019. The primary outcome was all-cause in-hospital mortality. The number of HF hospitalizations was significantly reduced during the COVID-19 pandemic, compared with 2019 (P < 0.001). Specifically, we observed a temporary reduction in hospitalizations during the COVID-19 peak, followed by a return to 2019 levels. Patients admitted during the COVID-19 pandemic had demographic characteristics similar to those admitted during the equivalent period in 2019. However, in-hospital mortality was significantly higher in 2020 than in 2019 (P = 0.015). Hospitalization in 2020 was independently associated with worse in-hospital mortality (hazard ratio 2.23, 95% confidence interval 1.34-3.72; P = 0.002).During the COVID-19 pandemic there was a reduction in HF hospitalization and a higher rate of in-hospital mortality. Hospitalization for HF in 2020 is independently associated with more adverse outcomes. Further studies are required to investigate the predictors of these adverse outcomes to help inform potential changes to the management of HF patients while some constraints to usual care remain.
Tyrosinase-activated prodrug nanomedicine as oxidative stress amplifier for melanoma-specific treatment
Authors: Yinying Pu, Bangguo Zhou, Huijing Xiang, Wencheng Wu, Haohao Yin, Wenwen Yue, Yifei Yin, Hongyan Li, Yu Chen, Huixiong Xu
Journal: Biomaterials (2020)
Hippocampal avoidance whole-brain radiotherapy without memantine in preserving neurocognitive function for brain metastases: a phase II blinded randomized trial
Authors: Wen-Chi Yang, Ya-Fang Chen, Chi-Cheng Yang, Pei-Fang Wu, Hsing-Min Chan, Jenny Ling-Yu Chen, Guann-Yiing Chen, Jason Chia-Hsien Cheng, Sung-Hsin Kuo, Feng-Ming Hsu
Journal: Neuro-Oncology (2020)

Hippocampal avoidance whole-brain radiotherapy (HA-WBRT) shows potential for neurocognitive preservation. This study aimed to evaluate whether HA-WBRT or conformal WBRT (C-WBRT) is better for preserving neurocognitive function.This single-blinded randomized phase II trial enrolled patients with brain metastases and randomly assigned them to receive HA-WBRT or C-WBRT. Primary endpoint is decline of the Hopkins Verbal Learning Test-Revised (HVLT-R) delayed recall at 4 months after treatment. Neurocognitive function tests were analyzed with a mixed effect model. Brain progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method.From March 2015 to December 2018, seventy patients were randomized to yield a total cohort of 65 evaluable patients (33 in the HA-WBRT arm and 32 in the C-WBRT arm) with a median follow-up of 12.4 months. No differences in baseline neurocognitive function existed between the 2 arms. The mean change of HVLT-R delayed recall at 4 months was -8.8% in the HA-WBRT arm and +3.8% in the C-WBRT arm (P = 0.31). At 6 months, patients receiving HA-WBRT showed favorable perpetuation of HVLT-R total recall (mean difference = 2.60, P = 0.079) and significantly better preservation of the HVLT-R recognition-discrimination index (mean difference = 1.78, P = 0.019) and memory score (mean difference = 4.38, P = 0.020) compared with patients undergoing C-WBRT. There were no differences in Trail Making Test Part A or Part B or the Controlled Oral Word Association test between the 2 arms at any time point. There were no differences in brain PFS or OS between arms as well.Patients receiving HA-WBRT without memantine showed better preservation in memory at 6-month follow-up, but not in verbal fluency or executive function.
Cancer in Systemic Sclerosis: Analysis of Antibodies Against Components of the Th/To Complex
Authors: Christopher A. Mecoli, Brittany L. Adler, Qingyuan Yang, Laura K. Hummers, Antony Rosen, Livia Casciola‐Rosen, Ami A. Shah
Journal: Arthritis & Rheumatology (2020)

Objective The aim of this study is to describe 4 of the most common autoantibodies against components of the Th/To complex: human POP1 (hPOP1), RPP25, RPP30, and RPP40. We report their prevalence and clinical characteristics in a systemic sclerosis (SSc) population, and determine whether these specificities are associated with cancer. Methods A case–control study was performed using data from the Johns Hopkins Scleroderma Center Cohort. A total of 804 adult patients with SSc were included; 401 SSc patients with no history of cancer after at least 5 years of disease were compared to 403 SSc patients who ever had a history of cancer. Antibodies against hPOP1, RPP25, RPP30, and RPP40 were assayed by immunoprecipitation of 35 S‐methionine–labeled proteins generated by in vitro transcription/translation. Demographic and clinical characteristics were compared between groups. Results Of 804 patients, 67 (8.3%) had antibodies against any component of the Th/To complex. Patients with antibodies to any component were significantly more likely to have limited cutaneous disease, less likely to have tendon friction rubs, and more likely to have findings consistent with interstitial lung disease or pulmonary hypertension. Patients with antibodies against hPOP1, RPP25, RPP30, and/or RPP40 were significantly less likely to develop cancer within 2 years of SSc onset (0% versus 11% of antibody‐negative patients; P = 0.009). Conclusion SSc patients who produce autoantibodies to components of the Th/To complex have a clinical phenotype characterized by limited cutaneous disease and pulmonary involvement. Our findings show that the presence of any Th/To autoantibody may have a protective effect against contemporaneous cancer.
THU0156 Do glucocorticoids affect muscle strength in rheumatoid arthritis (RA)?
Authors: OR Madsen, C Egsmose
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> It is common knowledge that treatment with steroids is accompanied by muscle wasting. However, only very limited data on the effect of steroids on muscle strength in RA are available in the literature. <h3>Objectives</h3> We examined the effect of cumulative and current prednisolone dose on leg muscle strength in women with RA. <h3>Methods</h3> Seventy-five women with RA according to the 1987 ACR criteria were included. Mean age was 62 ± 13 years, median disease duration 11 (1–51) years. Sixty-three were or had been on steroids [median cumulative prednisolone dose (CPD) 2.5 (0.05–66) g]. Maximal voluntary knee extensor strength (KES) and flexor strength (KFS) (Nm) were assessed at 30<sup>o</sup>/s by an isokinetic dynamometer. Based on the 25th and 75th centiles of the distribution of CPD, the women were stratified into those who had received a) 100 mg prednisolone or less (n = 21, median CPD = 0 mg), b) more than 100 mg but less than 6095 mg prednisolone (n = 35, median CPD = 2000 mg), and c) 6095 mg or more (n = 19, median CPD = 10771 mg). Adjustment for between-group differences in age, height, weight and disease duration was performed using ANOVA with correction for covariates. <h3>Results</h3> The following adjusted mean values for KES were found (low, central and high CPD range): 84 Nm, 76 Nm and 80 Nm (ns). The corresponding values for KFS were 44 Nm, 42 Nm and 42 Nm (ns). In<i> currently</i> treated subjects (n = 25) adjusted mean values for KES and KFS were 75 Nm and 39 Nm, respectively, vs. 70 Nm and 33 Nm in never-treated subjects (n = 12) (ns). <h3>Conclusion</h3> In conclusion, muscle strength was not associated with cumulative or current steroid dose in women with RA.
The protective effect of celecoxib, a cyclooxygenase-2 inhibitor, on aberrant crypt formation in rats administered 3,2’-dimethyl-4-aminobiphenyl
Authors: Yi Feng, Jason R. Neale, Mark A. Doll, David W. Hein
Journal: Cancer Research (2006)

3165  Colorectal cancer is among the most common malignancies worldwide. Cyclooxygenase-2 (COX-2) is overexpressed in colorectal adenomas and colorectal cancer. Celecoxib, a COX-2 inhibitor, has been approved for the treatment of patients with familial adenomatous polyposis. Aromatic amines are very prevalent environmental carcinogens and also are potent colorectal carcinogens in rodents and possibly humans. Aromatic amines are activated by COX-2. In this study, aberrant crypt foci (ACF), the preneoplastic lesions in colorectal carcinogenesis, were used as biomarkers to test the effect of celecoxib in aromatic amine-induced colorectal carcinogenesis. Male weanling F344 inbred rats were fed the modified AIN-76A (control) diet for one week. At five weeks of age, rats were fed the control or experimental diets containing 320 ppm sulindac or 500, 1000, or 1500 ppm celecoxib. At 7 weeks of age, rats received a subcutaneous injection of vehicle (peanut oil) or 3,2’-dimethyl-4-aminobiphenyl (DMABP), an aromatic amine colon carcinogen, once weekly for two weeks. At 17 weeks of age, all rats were euthanized and colorectums were removed, opened longitudinally, and fixed in 70% ethanol. ACF were analyzed under a dissecting microscope after 0.1% methylene blue staining. No ACF were identified in vehicle treated rats. In DMABP-treated rats, ACF frequencies decreased significantly (p 0.05) before DMABP administration at 4 and 7 weeks of age, but they were significantly higher (p
Abstract SY09-03: PROFYLEing Cancer for KiCS: The Canadian Pediatric Precision Oncology Initiative
Authors: David Malkin, Jason N. Berman, Jennifer A. Chan, Avram Denburg, Rebecca Deyell, David Eisenstadt, Conrad Fernandez, Stephanie Grover, Abha Gupta, Cynthia Hawkings, Meredith Irwin, Nada Jabado, Steven Jones, Daniel Morgenstern, Michael Moran, Rod Rasesekh, Adam Shlien, Daniel Sinnett, Poul Sorensen, Patrick Sullivan, Michael Taylor, Anita Villani, Jim Whitlock
Journal: Cancer Research (2020)

Abstract Each year, approximately 4300 children, adolescents and young adults (CAYA) are diagnosed with cancer. One-third of these patients present with metastatic disease, develop refractory disease or relapse. For these patients, the likelihood of survival remains grim and essentially unchanged in more than three decades. Precision Oncology for Young PeopLE (PROFYLE) is a pan-Canadian, interdisciplinary program that was built on the foundation of three major sequencing efforts in Vancouver (PedsPOG), Toronto (KiCS) and Montreal (TRICEPS) for children with hard-to-treat cancer. Since its inception in 2017, over 700 patients have had complete NGS of paired blood-tumor samples with a goal to not only develop a national precision oncology pipeline, but also to determine the frequency and spectrum of molecular targets for novel therapies and other clinically actionable findings. During this presentation, both the process as well as current findings will be presented and plans for the future will be outlined. Citation Format: David Malkin, Jason N. Berman, Jennifer A. Chan, Avram Denburg, Rebecca Deyell, David Eisenstadt, Conrad Fernandez, Stephanie Grover, Abha Gupta, Cynthia Hawkings, Meredith Irwin, Nada Jabado, Steven Jones, Daniel Morgenstern, Michael Moran, Rod Rasesekh, Adam Shlien, Daniel Sinnett, Poul Sorensen, Patrick Sullivan, Michael Taylor, Anita Villani, Jim Whitlock. PROFYLEing Cancer for KiCS: The Canadian Pediatric Precision Oncology Initiative [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr SY09-03.